$CNSP
CNS Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000168316824005711 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.384M $1.412M
YoY Change 23.2% 19.64%
% of Gross Profit
Research & Development $4.245M $1.117M
YoY Change 24.47% -60.76%
% of Gross Profit
Depreciation & Amortization $750.00 $750.00
YoY Change -76.42% -25.0%
% of Gross Profit
Operating Expenses $5.629M $2.528M
YoY Change 24.15% -37.2%
Operating Profit -$5.629M -$2.528M
YoY Change 24.15% -37.2%
Interest Expense $22.97K -$2.610K
YoY Change 1149.73% -171.51%
% of Operating Profit
Other Income/Expense, Net $22.97K -$2.618K
YoY Change 107.99% -163.05%
Pretax Income -$5.606M -$2.531M
YoY Change 23.95% -37.07%
Income Tax
% Of Pretax Income
Net Earnings -$5.606M -$2.531M
YoY Change 23.95% -37.07%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$6.72
Diluted Earnings Per Share -$0.25 -$6.72
COMMON SHARES
Basic Shares Outstanding 32.15M shares 10.63M shares
Diluted Shares Outstanding 22.18M shares 376.6K shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.973M $1.492M
YoY Change 666.66% -65.14%
Cash & Equivalents $6.973M $1.492M
Short-Term Investments
Other Short-Term Assets $415.0K $653.8K
YoY Change -63.99% -63.51%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.388M $2.145M
YoY Change 258.32% -64.66%
LONG-TERM ASSETS
Property, Plant & Equipment $2.802K $3.553K
YoY Change -19.25% 5.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.37K $320.3K
YoY Change -93.01% -15.08%
Total Long-Term Assets $21.18K $323.9K
YoY Change -92.05% -14.9%
TOTAL ASSETS
Total Short-Term Assets $7.388M $2.145M
Total Long-Term Assets $21.18K $323.9K
Total Assets $7.409M $2.469M
YoY Change 218.26% -61.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.026M $6.640M
YoY Change -0.03% 85.95%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $31.19K $123.3K
YoY Change -25.56% -25.93%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.057M $6.763M
YoY Change -0.29% 69.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.057M $6.763M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.057M $6.763M
YoY Change -0.29% 69.19%
SHAREHOLDERS EQUITY
Retained Earnings -$81.25M -$75.64M
YoY Change 26.57% 26.77%
Common Stock $33.45K $1.443K
YoY Change 695.01% -65.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.352M -$4.294M
YoY Change
Total Liabilities & Shareholders Equity $7.409M $2.469M
YoY Change 218.26% -61.73%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$5.606M -$2.531M
YoY Change 23.95% -37.07%
Depreciation, Depletion And Amortization $750.00 $750.00
YoY Change -76.42% -25.0%
Cash From Operating Activities -$6.800M -$1.650M
YoY Change 101.56% -51.5%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.28M 2.327M
YoY Change 128368.1% -9.52%
NET CHANGE
Cash From Operating Activities -6.800M -1.650M
Cash From Investing Activities 0.000
Cash From Financing Activities 12.28M 2.327M
Net Change In Cash 5.482M 676.3K
YoY Change -262.86% -181.36%
FREE CASH FLOW
Cash From Operating Activities -$6.800M -$1.650M
Capital Expenditures $0.00
Free Cash Flow -$6.800M
YoY Change 101.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39126
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2528135 usd
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CNSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Entity Registrant Name
EntityRegistrantName
CNS Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2318545
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 West Loop South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
946-9185
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32146403 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1491559 usd
CY2024Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
16750 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
637087 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
2145396 usd
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
320320 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3553 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
323873 usd
CY2024Q2 us-gaap Assets
Assets
2469269 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
123248 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6762870 usd
CY2024Q2 us-gaap Liabilities
Liabilities
6762870 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1443274 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1443274 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124306 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124306 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1443 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
71347360 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75642404 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4293601 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2469269 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6639622 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1411573 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1116562 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
2528135 usd
CY2024Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1845 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4463 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2618 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2530753 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.72
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.72
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376643 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376643 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4432115 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3330998 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12405 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202933 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3544748 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4430527 usd
CY2024Q2 CNSP Common Stock Issued For Cash And Warrants Net
CommonStockIssuedForCashAndWarrantsNet
2424413 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
8921 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
234345 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2530753 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4293601 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
609 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
290313 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4931947 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3491831 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1969107 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
725059 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
289670 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4021234 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2454433 usd
us-gaap Net Income Loss
NetIncomeLoss
-6075501 usd
us-gaap Net Income Loss
NetIncomeLoss
-8953181 usd
us-gaap Share Based Compensation
ShareBasedCompensation
437278 usd
us-gaap Share Based Compensation
ShareBasedCompensation
579983 usd
us-gaap Depreciation
Depreciation
1570 usd
us-gaap Depreciation
Depreciation
2282 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
190 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13067 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-823073 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
807460 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-679516 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4842450 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8227359 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
16750 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
-0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
177558 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
243572 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
21326 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
725668 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5958270 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1969107 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5785288 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2451203 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
942838 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5776156 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
548721 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10055407 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1491559 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4279251 usd
us-gaap Interest Paid Net
InterestPaidNet
11088 usd
us-gaap Interest Paid Net
InterestPaidNet
9086 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CNSP Reclassification Of Deferred Offering Costs To Equity
ReclassificationOfDeferredOfferingCostsToEquity
202859 usd
CNSP Reclassification Of Deferred Offering Costs To Equity
ReclassificationOfDeferredOfferingCostsToEquity
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_802_eus-gaap--NatureOfOperations_zYhVSBlsYDRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_82D_z1Ytfkbf6Kz3">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 25, 2022, the stockholders of the Company approved an amendment to the Company’s amended and restated articles of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-30. The reverse stock split became effective on November 28, 2022 on a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20221127__20221128_zYDygP9hVKy6">1-for-30</span> basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 30, 2024, the stockholders of the Company approved an amendment to the Company’s amended and restated articles of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-50. The reverse stock split became effective on June 4, 2024 on a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20240603__20240604_zHew1ogLTQAe">1-for-50</span> basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30
CY2024Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-50
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1241559 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30
CY2024Q1 us-gaap Shares Issued
SharesIssued
44314 shares
CY2024Q1 us-gaap Share Price
SharePrice
0.001
CY2024Q1 CNSP Purchase Of Prefunded Warrants
PurchaseOfPrefundedWarrants
222354 shares
CY2024Q2 CNSP Purchase Of Prefunded Warrants Exercised
PurchaseOfPrefundedWarrantsExercised
44094 shares
CY2024Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3331000 usd
CNSP Fair Value Of Common Stock On Measurement Date
FairValueOfCommonStockOnMeasurementDate
$12.65 to $12.93 per share
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M29D
CY2024Q1 CNSP Warrant Amendment Agreement Description
WarrantAmendmentAgreementDescription
Company agreed, subject to shareholder approval (which was received on April 30, 2024), to amend certain existing warrants to purchase up to an aggregate of 75,120 shares of Common Stock at an exercise price of $64.00 per share and a termination date of October 16, 2028, so that the amended warrants will have a reduced exercise price of $15.00 per share and a new termination date of February 1, 2029.
CY2023Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
2500000 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-005711-index-headers.html Edgar Link pending
0001683168-24-005711-index.html Edgar Link pending
0001683168-24-005711.txt Edgar Link pending
0001683168-24-005711-xbrl.zip Edgar Link pending
cnsp-20240630.xsd Edgar Link pending
cns_ex3101.htm Edgar Link pending
cns_ex3102.htm Edgar Link pending
cns_ex3201.htm Edgar Link pending
cns_ex3202.htm Edgar Link pending
cns_i10q-063024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
cnsp-20240630_cal.xml Edgar Link unprocessable
cnsp-20240630_def.xml Edgar Link unprocessable
cnsp-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cns_i10q-063024_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnsp-20240630_pre.xml Edgar Link unprocessable